C4 Therapeutics Stock Market Value
| CCCC Stock | USD 1.83 0.01 0.54% |
| Symbol | CCCC |
Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.67) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value - what C4 Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
C4 Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to C4 Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of C4 Therapeutics.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in C4 Therapeutics on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding C4 Therapeutics or generate 0.0% return on investment in C4 Therapeutics over 90 days. C4 Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade dise... More
C4 Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure C4 Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess C4 Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 25.16 | |||
| Value At Risk | (7.00) | |||
| Potential Upside | 8.06 |
C4 Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for C4 Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as C4 Therapeutics' standard deviation. In reality, there are many statistical measures that can use C4 Therapeutics historical prices to predict the future C4 Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.67) | |||
| Treynor Ratio | (0.19) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of C4 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
C4 Therapeutics February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 3.3 | |||
| Coefficient Of Variation | (1,629) | |||
| Standard Deviation | 4.47 | |||
| Variance | 20.02 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.67) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 25.16 | |||
| Value At Risk | (7.00) | |||
| Potential Upside | 8.06 | |||
| Skewness | 0.7307 | |||
| Kurtosis | 1.74 |
C4 Therapeutics Backtested Returns
C4 Therapeutics retains Efficiency (Sharpe Ratio) of -0.09, which signifies that the company had a -0.09 % return per unit of price deviation over the last 3 months. C4 Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm C4 Therapeutics' Market Risk Adjusted Performance of (0.18), variance of 20.02, and Information Ratio of (0.08) to double-check the risk estimate we provide. The firm owns a Beta (Systematic Risk) of 1.51, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, C4 Therapeutics will likely underperform. At this point, C4 Therapeutics has a negative expected return of -0.42%. Please make sure to confirm C4 Therapeutics' mean deviation, information ratio, potential upside, as well as the relationship between the standard deviation and total risk alpha , to decide if C4 Therapeutics performance from the past will be repeated sooner or later.
Auto-correlation | 0.78 |
Good predictability
C4 Therapeutics has good predictability. Overlapping area represents the amount of predictability between C4 Therapeutics time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of C4 Therapeutics price movement. The serial correlation of 0.78 indicates that around 78.0% of current C4 Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.78 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out C4 Therapeutics Correlation, C4 Therapeutics Volatility and C4 Therapeutics Performance module to complement your research on C4 Therapeutics. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
C4 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.